
Keywords: AZ; acetazolamide; IM; imatinib; EAC; Ehrlich ascites carcinoma; PDGF-A; platelet derived growth factor-A; TSP-1; thrombospondin-1; VEGF; vascular endothelial growth factor; NO; nitric oxide; MMP; matrix metalloproteinase; MAPK; mitogen activated protein